These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 21301341)
1. Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Roobol MJ Curr Opin Urol; 2011 May; 21(3):225-9. PubMed ID: 21301341 [TBL] [Abstract][Full Text] [Related]
2. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709 [TBL] [Abstract][Full Text] [Related]
3. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322 [TBL] [Abstract][Full Text] [Related]
4. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100). Roobol MJ; Schröder FH; van Leenders GL; Hessels D; van den Bergh RC; Wolters T; van Leeuwen PJ Eur Urol; 2010 Dec; 58(6):893-9. PubMed ID: 20933321 [TBL] [Abstract][Full Text] [Related]
5. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). Kirby RS; Fitzpatrick JM; Irani J BJU Int; 2009 Feb; 103(4):441-5. PubMed ID: 19154510 [TBL] [Abstract][Full Text] [Related]
6. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Fradet Y Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493 [TBL] [Abstract][Full Text] [Related]
7. PCA3: from basic molecular science to the clinical lab. Day JR; Jost M; Reynolds MA; Groskopf J; Rittenhouse H Cancer Lett; 2011 Feb; 301(1):1-6. PubMed ID: 21093148 [TBL] [Abstract][Full Text] [Related]
8. Progensa™ PCA3 test for prostate cancer. Durand X; Moutereau S; Xylinas E; de la Taille A Expert Rev Mol Diagn; 2011 Mar; 11(2):137-44. PubMed ID: 21405964 [TBL] [Abstract][Full Text] [Related]
9. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? Ploussard G; Haese A; Van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Bastien L; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; Van Gils MP; Schalken JA; de La Taille A BJU Int; 2010 Oct; 106(8):1143-7. PubMed ID: 20230386 [TBL] [Abstract][Full Text] [Related]
10. Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice. Schilling D; Hennenlotter J; Munz M; Bökeler U; Sievert KD; Stenzl A Urol Int; 2010; 85(2):159-65. PubMed ID: 20424427 [TBL] [Abstract][Full Text] [Related]
11. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. Salagierski M; Schalken JA J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323 [TBL] [Abstract][Full Text] [Related]
12. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159 [TBL] [Abstract][Full Text] [Related]
13. Biomarkers for prostate cancer detection. Reed AB; Parekh DJ Expert Rev Anticancer Ther; 2010 Jan; 10(1):103-14. PubMed ID: 20014890 [TBL] [Abstract][Full Text] [Related]
14. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. van Gils MP; Hessels D; van Hooij O; Jannink SA; Peelen WP; Hanssen SL; Witjes JA; Cornel EB; Karthaus HF; Smits GA; Dijkman GA; Mulders PF; Schalken JA Clin Cancer Res; 2007 Feb; 13(3):939-43. PubMed ID: 17289888 [TBL] [Abstract][Full Text] [Related]
15. [Value of urinary PCA3 test for prostate cancer diagnosis]. Vlaeminck-Guillem V; Ruffion A; Andre J Prog Urol; 2008 May; 18(5):259-65. PubMed ID: 18538269 [TBL] [Abstract][Full Text] [Related]
16. PCA3: a molecular urine assay for predicting prostate biopsy outcome. Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257 [TBL] [Abstract][Full Text] [Related]
17. The Prostate Cancer gene 3 assay: indications for use in clinical practice. Schilling D; de Reijke T; Tombal B; de la Taille A; Hennenlotter J; Stenzl A BJU Int; 2010 Feb; 105(4):452-5. PubMed ID: 19930176 [TBL] [Abstract][Full Text] [Related]
18. [Markers for diagnosis, prediction and prognosis of prostate cancer]. Taskén KA; Angelsen A; Svindland A; Eide T; Berge V; Wahlquist R; Karlsen S Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3279-82. PubMed ID: 16327854 [TBL] [Abstract][Full Text] [Related]
19. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era. Bickers B; Aukim-Hastie C Anticancer Res; 2009 Aug; 29(8):3289-98. PubMed ID: 19661347 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of serum markers for prostate cancer. Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]